Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

被引:192
作者
White, Ann L. [1 ]
Chan, H. T. Claude [1 ]
Roghanian, Ali [1 ]
French, Ruth R. [1 ]
Mockridge, C. Ian [1 ]
Tutt, Alison L. [1 ]
Dixon, Sandra V. [1 ]
Ajona, Daniel [1 ]
Verbeek, J. Sjef [2 ]
Al-Shamkhani, Aymen [1 ]
Cragg, Mark S. [1 ]
Beers, Stephen A. [1 ]
Glennie, Martin J. [1 ]
机构
[1] Univ Southampton, Fac Med, Div Canc Sci, Southampton SO16 6YD, Hants, England
[2] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands
关键词
C-RECEPTOR POLYMORPHISMS; T-CELL TOLERANCE; IN-VIVO; CD20; IMMUNOTHERAPY; CD40; PATHWAY; B-CELLS; LYMPHOMA; CANCER; THERAPY; TUMOR;
D O I
10.4049/jimmunol.1101135
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A high activatory/inhibitory Fc gamma R binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal Fc gamma R binding profiles of other anti-cancer mAb, such as immunostimulatory mAb that stimulate or block immune receptors, are less clear. In this study, we analyzed the importance of isotype and Fc gamma R interactions in controlling the agonistic activity of the anti-mouse CD40 mAb 3/23. Mouse IgG1 (m1) and IgG2a (m2a) variants of the parental 3/23 (rat IgG2a) were engineered and used to promote humoral and cellular responses against OVA. The mouse IgG1 3/23 was highly agonistic and outperformed the parental Ab when promoting Ab (10-100-fold) and T cell (OTI and OTII) responses (2- to >10-fold). In contrast, m2a was almost completely inactive. Studies in Fc gamma R knockout mice demonstrated a critical role for the inhibitory Fc gamma RIIB in 3/23 activity, whereas activatory Fc gamma R (Fc gamma RI, -III, and -IV) was dispensable. In vitro experiments established that the stimulatory effect of Fc gamma RIIB was mediated through Ab cross-linking delivered in trans between neighboring cells and did not require intracellular signaling. Intriguingly, activatory Fc gamma R provided effective cross-linking of 3/23 m2a in vitro, suggesting the critical role of Fc gamma RIIB in vivo reflects its cellular distribution and bioavailability as much as its affinity for a particular Ab isotype. In conclusion, we demonstrate an essential cross-linking role for the inhibitory Fc gamma RIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use. The Journal of Immunology, 2011, 187: 1754-1763.
引用
收藏
页码:1754 / 1763
页数:10
相关论文
共 55 条
[1]   Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma [J].
Advani, Ranjana ;
Forero-Torres, Andres ;
Furman, Richard R. ;
Rosenblatt, Joseph D. ;
Younes, Anas ;
Ren, Hong ;
Harrop, Kate ;
Whiting, Nancy ;
Drachman, Jonathan G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4371-4377
[2]   CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].
Beatty, Gregory L. ;
Chiorean, Elena G. ;
Fishman, Matthew P. ;
Saboury, Babak ;
Teitelbaum, Ursina R. ;
Sun, Weijing ;
Huhn, Richard D. ;
Song, Wenru ;
Li, Dongguang ;
Sharp, Leslie L. ;
Torigian, Drew A. ;
O'Dwyer, Peter J. ;
Vonderheide, Robert H. .
SCIENCE, 2011, 331 (6024) :1612-1616
[3]   Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection [J].
Beers, Stephen A. ;
French, Ruth R. ;
Chan, H. T. Claude ;
Lim, Sean H. ;
Jarrett, Timothy C. ;
Vidal, Regina Mora ;
Wijayaweera, Sahan S. ;
Dixon, Sandra V. ;
Kim, Hyungjin ;
Cox, Kerry L. ;
Kerr, Jonathan P. ;
Johnston, David A. ;
Johnson, Peter W. M. ;
Verbeek, J. Sjef ;
Glennie, Martin J. ;
Cragg, Mark S. .
BLOOD, 2010, 115 (25) :5191-5201
[4]   CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies [J].
Beers, Stephen A. ;
Chan, Claude H. T. ;
French, Ruth R. ;
Cragg, Mark S. ;
Glennie, Martin J. .
SEMINARS IN HEMATOLOGY, 2010, 47 (02) :107-114
[5]   Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan [J].
Bibeau, Frederic ;
Lopez-Crapez, Evelyne ;
Di Fiore, Frederic ;
Thezenas, Simon ;
Ychou, Marc ;
Blanchard, France ;
Lamy, Aude ;
Penault-Llorca, Frederique ;
Frebourg, Thierry ;
Michel, Pierre ;
Sabourin, Jean-Christophe ;
Boissiere-Michot, Florence .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1122-1129
[6]   Absence of Tapasin Alters Immunodominance against a Lymphocytic Choriomeningitis Virus Polytope [J].
Boulanger, Denise S. M. ;
Oliveira, Roberta ;
Ayers, Lisa ;
Prior, Stephen H. ;
James, Edward ;
Williams, Anthony P. ;
Elliott, Tim .
JOURNAL OF IMMUNOLOGY, 2010, 184 (01) :73-83
[7]   Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses [J].
Bruhns, Pierre ;
Iannascoli, Bruno ;
England, Patrick ;
Mancardi, David A. ;
Fernandez, Nadine ;
Jorieux, Sylvie ;
Daeron, Marc .
BLOOD, 2009, 113 (16) :3716-3725
[8]   Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758
[9]   CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses [J].
Castro, Fernanda V. V. ;
Tutt, Alison L. ;
White, Ann L. ;
Teeling, Jessica L. ;
James, Sonya ;
French, Ruth R. ;
Glennie, Martin J. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (08) :2263-2273
[10]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446